532 related articles for article (PubMed ID: 22510564)
21. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
22. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
[TBL] [Abstract][Full Text] [Related]
23. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
Zhang X; Schulz R; Edmunds S; Krüger E; Markert E; Gaedcke J; Cormet-Boyaka E; Ghadimi M; Beissbarth T; Levine AJ; Moll UM; Dobbelstein M
Mol Cell; 2015 Jul; 59(2):243-57. PubMed ID: 26145175
[TBL] [Abstract][Full Text] [Related]
25. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
An WG; Hwang SG; Trepel JB; Blagosklonny MV
Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
[TBL] [Abstract][Full Text] [Related]
26. Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341.
Lee C; Waldman T
Cancer Biol Ther; 2003; 2(6):700-1. PubMed ID: 14688480
[No Abstract] [Full Text] [Related]
27. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
28. BU-32: a novel proteasome inhibitor for breast cancer.
Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
[TBL] [Abstract][Full Text] [Related]
29. The proteasome.
Dalton WS
Semin Oncol; 2004 Dec; 31(6 Suppl 16):3-9; discussion 33. PubMed ID: 15799238
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition in cancer: development of PS-341.
Adams J
Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
[TBL] [Abstract][Full Text] [Related]
31. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic potential of deubiquitinating enzyme inhibitors.
Colland F
Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048
[TBL] [Abstract][Full Text] [Related]
33. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
Yerlikaya A; Okur E; Ulukaya E
Tumour Biol; 2012 Oct; 33(5):1385-92. PubMed ID: 22477712
[TBL] [Abstract][Full Text] [Related]
34. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Colland F
IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
[No Abstract] [Full Text] [Related]
35. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
37. Targeting Deubiquitinases in Cancer.
Bednash JS; Mallampalli RK
Methods Mol Biol; 2018; 1731():295-305. PubMed ID: 29318562
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
[TBL] [Abstract][Full Text] [Related]
39. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
40. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
Selvendiran K; Tong L; Vishwanath S; Bratasz A; Trigg NJ; Kutala VK; Hideg K; Kuppusamy P
J Biol Chem; 2007 Sep; 282(39):28609-28618. PubMed ID: 17684018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
